MedDataX Logo

Lipoic Acid Supplement for Cystine Stone

NCT02910531 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-12-20

No results posted yet for this study

Summary

This study evaluates how daily alpha lipoic acid supplementation affects cystine kidney stone recurrence. Half of the subjects will receive 1200 mg alpha lipoic acid orally daily for three years, while the other half will receive a placebo. The funding source for this clinical trial is FDA OOPD.

Conditions

  • Cystinuria

Interventions

DIETARY_SUPPLEMENT

Alpha lipoic acid

Already mentioned in arm/group descriptions.

DRUG

Placebo

Already mentioned in arm/group descriptions.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Thomas Chi, MD

    lead OTHER

Principal Investigators

  • Thomas Chi, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-19
Primary Completion
2024-06-30
Completion
2025-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02910531 on ClinicalTrials.gov